StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Mineralys Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Mineralys Therapeutics

Mineralys Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Mineralys Therapeutics figures

See a number that looks wrong?